DOCSLIB.ORG

Identification and Characterisation of SMIM1 Variants Determining the Vel Blood Group

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification and Characterisation of SMIM1 Variants Determining the Vel Blood Group Identification and characterisation of SMIM1 variants determining the Vel blood group Christophersen, Mikael Kronborg 2017 Document Version: Publisher's PDF, also known as Version of record Link to publication Citation for published version (APA): Christophersen, M. K. (2017). Identification and characterisation of SMIM1 variants determining the Vel blood group. Lund University: Faculty of Medicine. Total number of authors: 1 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 Download date: 02. Oct. 2021 Identification and characterisation of SMIM1 variants determining the Vel blood group Mikael Kronborg Christophersen DOCTORAL DISSERTATION by due permission of the Faculty of Medicine, Lund University, Sweden. To be defended at 13:00 on Thursday 30th March 2017 at Biomedicinsk Centrum, Segerfalksalen Faculty opponent Associate Professor Morten Hanefeld Dziegiel Organization Document name LUND UNIVERSITY DOCTORAL DISSERTATION Department of Laboratory Medicine Date of issue Division of Hematology and Transfusion Medicine March 30th 2017 Author(s) Mikael Kronborg Christophersen Sponsoring organization Title and subtitle Identification and characterisation of SMIM1 variants determining the Vel blood group Abstract The Vel blood group antigen is present on red blood cells from all humans except rare Vel-negative individuals, who can form antibodies to Vel in response to transfusion or pregnancy. It was first described in 1952 as a high incidence antigen, while the molecular background was recently discovered to be a 17-bp deletion in Small Integral Membrane Protein 1, that causes a frame-shift mutation and abolishes SMIM1 expression, thus creating a Vel-negative phenotype. This thesis contains one of the three original discovery studies reporting the Vel antigen-defining SMIM1- deletion. We analysed SNP microarray data from Vel-positive and -negative individuals and identified SMIM1 as a potential gene. We then found the 17-bp deletion to only be present in Vel-negative individuals and sought to finally prove SMIM1 as the genetic background for the Vel antigen by examining: 1) SMIM1 mRNA sequence and expression levels, 2) presence of SMIM1 and the Vel antigen in red blood cell membranes from Vel-positive and -negative individuals and 3) anti-Vel antibody reactivity in erythroleukaemia cells expressing wild type and mutant SMIM1 protein. Our discovery allowed Vel to be officially recognised by the International Society of Blood Transfusion as blood group system 034. The SMIM1 deletion is the major determinant for Vel expression, yet even Vel-positive individuals (i.e. people carrying wild type SMIM1) show substantial variation in reactivity with anti-Vel antibody, creating a risk for Vel blood typing errors and transfusion reactions. We suspected the cause to be sequence variants in SMIM1 and found rs143702418 (insertion, C>CGCA) and rs1175550 (A>G) to independently influence expression of SMIM1, potentially mediated by the erythroid transcription factor TAL1 that binds preferentially to the high- expressing rs1175550G allele. Lastly, we examined historical Vel-negative samples and sought to retroactively reconcile historic Vel designations to our current knowledge of the SMIM1 deletion variant. As such, we found the old Vel;–1,–2 designation, attributed to individuals phenotyped to have weak to no Vel antigen expression, to correspond to homozygosity for the SMIM1 deletion, while persons designated Vel;1,–2, low Vel antigen expression, matched with being heterozygous carrier of the deletion. The Vel antigen was one of the few remaining clinically significant antigens with unknown genetic background, that causes severe haemolytic transfusion reactions. This thesis assisted in characterising the molecular background of the Vel antigen, which paved the way for molecular Vel typing in the clinic, as well as the prospect of manufacturing a synthetic monoclonal anti-Vel antibody to be used in diagnostics, blood group typing and research. Key words Blood groups, Vel blood group system, genetic variation, transcriptional regulation Classification system and/or index terms (if any) Supplementary bibliographical information Language English ISSN and key title 1652-8220 ISBN 978-91-7619-428-7 Recipient’s notes Number of pages 94 Price Security classification I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation. Signature Date February 22nd 2017 Identification and characterisation of SMIM1 variants determining the Vel blood group Mikael Kronborg Christophersen © Mikael Kronborg Christophersen Faculty of Medicine Department of Laboratory Medicine Division of Hematology and Transfusion Medicine Cover photos by Camilla Nehammer ISSN 1652-8220 ISBN 978-91-7619-428-7 Lund University, Faculty of Medicine Doctoral Dissertation Series 2017:48 Printed in Sweden by Media-Tryck, Lund University Lund 2017 Yet an experiment, were you to try it, could free you from your cavil, and the source of your arts' course springs from experiment. -Dante Alighieri: The Divine Comedy Preface The following PhD thesis details the results obtained through four years of research at the Division of Haematology and Transfusion Medicine, Lund University. It consists of three studies focusing on the Vel blood group system and one studying the disease multiple myeloma. Three studies have been published in Nature Genetics, Scientific Reports and Blood and one is an almost submission- ready manuscript. The Vel blood group antigen is present on red blood cells from all humans except rare Vel-negative individuals who can form antibodies to Vel in response to transfusion or pregnancy. It was first described in 1952 as a high incidence antigen, while the molecular background was recently discovered to be a 17-bp deletion in Small Integral Membrane Protein 1, that causes a frame-shift mutation and abolishes SMIM1 expression, thus creating a Vel-negative phenotype. This thesis contains one of the three original discovery studies reporting the Vel antigen-defining SMIM1-deletion. We analysed SNP microarray data from Vel- positive and -negative individuals and identified SMIM1 as a potential gene. We then found the 17-bp deletion to only be present in Vel-negative individuals and sought to finally prove SMIM1 as the genetic background for the Vel antigen by examining: 1) SMIM1 mRNA sequence and expression levels, 2) presence of SMIM1 and the Vel antigen in red blood cell membranes from Vel-positive and - negative individuals and 3) anti-Vel antibody reactivity in red blood cells from individuals homozygous or heterozygous for the 17-bp deletion and in erythroleukaemia cells expressing wild type and mutant SMIM1 protein. Our discovery allowed Vel to be officially recognised by the International Society of Blood Transfusion as blood group system 034. The SMIM1 deletion is the major determinant for Vel expression, yet even Vel- positive individuals show substantial variation in reactivity with anti-Vel antibody, creating a risk for Vel blood typing errors and transfusion reactions. We suspected the cause to be sequence variants in SMIM1 and found rs143702418 (insertion, C>CGCA) and rs1175550 (A>G) to independently influence expression of SMIM1, potentially mediated by the erythroid transcription factor TAL1 that binds preferentially to the high-expressing rs1175550G allele. Lastly, we examined historical Vel-negative samples and sought to retroactively reconcile historic Vel designations to our current knowledge of the SMIM1 deletion variant. As such, we found the old Vel;–1,–2 designation, attributed to individuals phenotyped to have weak to no Vel antigen expression, to correspond to homozygosity for the SMIM1 deletion, while persons designated Vel;1,–2, i.e. low Vel antigen expression, matched with being heterozygous carrier of the deletion. This thesis assisted in characterising the molecular background of the Vel antigen, which paved the way for molecular Vel typing in the clinic as well as the prospect of manufacturing a synthetic monoclonal anti-Vel antibody to be used in diagnostics, blood group typing and research. The final Study IV details the discovery of robust biomarkers for improved FACS sorting of multiple myeloma plasma cells in a bone marrow sample, a project I was involved in during the first year of my PhD. The thesis is divided into four main sections: An introduction outlining haematopoiesis, erythroid transcription factors, blood group systems
Load more

Recommended publications
  • Genetic Screening for the Vel- Phenotype Circumvents Difficult Serological Screening Due to Variable Vel Expression Levels
    UvA-DARE (Digital Academic Repository) Genetic basis of rare blood group variants Wigman, L. Publication date 2013 Link to publication Citation for published version (APA): Wigman, L. (2013). Genetic basis of rare blood group variants. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:28 Sep 2021 Chapter 6 Genetic screening for the Vel- phenotype circumvents difficult serological screening due to variable Vel expression levels Lonneke Haer-Wigman1 Shabnam Solati1 Aïcha Ait Soussan1 Erik Beckers2 Pim van der Harst3 Marga van Hulst-Sundermeijer4 Peter Ligthart1 Dick van Rhenen5 Hein Schepers3 Tamara Stegmann1 Masja de Haas1 C. Ellen van der Schoot1 1 Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands 2 Maastricht University Medical Centre+, Maastricht, The Netherlands 3 University Medical Center Groningen, University of Groningen, Groningen, The Netherlands 4 Sanquin Diagnostic Services, Amsterdam, The Netherlands 5 Sanquin Blood Bank, Rotterdam, Netherlands Manuscript under preparation Chapter 6 Abstract Background: Serological determination of the Vel- phenotype is challenging due to variable Vel expression levels.
    [Show full text]
  • Blood Group Genomics
    BLOOD GROUP GENOMICS Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of 36 blood group alleles among 396 Thai samples reveals region-specific variants Philaiphon Jongruamklang,1 Christoph Gassner,2 Stefan Meyer,2 Aksarakorn Kummasook,3 Marion Darlison,1 Chayanun Boonlum,4 Surin Chanta,5 Beat M. Frey,2 Martin L. Olsson,1,6* and Jill R. Storry 1,6* lood group antigen polymorphism shows great BACKGROUND: Blood group phenotype variation has variation in different world populations. The been attributed to potential resistance to pathogen reason for this is not completely understood; invasion. Variation was mapped in blood donors from however, it has been attributed to both Lampang (northern region) and Saraburi (central region), B Thailand, where malaria is endemic. The previously unknown blood group allele profiles were characterized ABBREVIATIONS: MALDI-TOF MS 5 matrix-assisted laser and the data were correlated with phenotypes. The high desorption/ionization time-of-flight mass spectrometry; PCR- incidence of the Vel-negative phenotype previously ASP 5 polymerase chain reaction with allele-specific reported in Thais was investigated. primers; SNP(s) 5 single nucleotide polymorphism(s). STUDY DESIGN AND METHODS: DNA from 396 From 1Hematology and Transfusion Medicine, Department of blood donors was analyzed by matrix-assisted laser Laboratory Medicine, Lund University, Lund, Sweden; desorption/ionization–time-of-flight mass spectrometry. 2Molecular Diagnostics & Research (MOC), Blood Transfusion Outliers were investigated by serology and DNA Service Zurich,€ Zurich-Schlieren,€ Switzerland; 3Department of sequencing. Allele discrimination assays for SMIM1 Medical Technology, School of Allied Health Sciences, rs1175550A/G and ACKR1 rs118062001C/T were University of Phayao, Phayao, Thailand; 4Transfusion Medicine, performed and correlated with antigen expression.
    [Show full text]
  • Comprehensive Red Blood Cell and Platelet Antigen Prediction from Whole Genome Sequencing: Proof of Principle
    BLOOD GROUP GENOMICS Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle William J. Lane,1,2 Connie M. Westhoff,3 Jon Michael Uy,1 Maria Aguad,1 Robin Smeland-Wagman,1 Richard M. Kaufman,1 Heidi L. Rehm,1,2,4,5 Robert C. Green,2,5,6 and Leslie E. Silberstein7 for the MedSeq Project* rediction of red blood cell (RBC) and platelet BACKGROUND: There are 346 serologically defined (PLT) antigens using DNA assays has the poten- red blood cell (RBC) antigens and 33 serologically tial to augment or replace traditional serologic defined platelet (PLT) antigens, most of which have antigen typing in many situations. DNA-based known genetic changes in 45 RBC or six PLT genes that P typing methods are more easily automated, amenable to correlate with antigen expression. Polymorphic sites multiplexing, and do not require expensive and some- associated with antigen expression in the primary times difficult to obtain serologic immunoglobulin literature and reference databases are annotated according to nucleotide positions in cDNA. This makes antigen prediction from next-generation sequencing data ABBREVIATIONS: CDS 5 coding DNA sequence; NGS 5 challenging, since it uses genomic coordinates. next-generation sequencing; SNP(s) 5 single-nucleotide STUDY DESIGN AND METHODS: The conventional polymorphism(s); WGS 5 whole genome sequencing. cDNA reference sequences for all known RBC and PLT From the 1Department of Pathology, the 6Division of Genetics, genes that correlate with antigen expression were Department of Medicine, and the 7Division of Transfusion aligned to the human reference genome. The alignments Medicine, Department of Pathology, Brigham and Women’s allowed conversion of conventional cDNA nucleotide Hospital; and 2Harvard Medical School, Boston, Massachusetts; positions to the corresponding genomic coordinates.
    [Show full text]
  • Clinical Significance of Antibodies to Antigens in the Raph, John Milton
    R EVIEW Proceedings from the International Society of Blood Transfusion Working Party on Immunohaematology, Workshop on the Clinical Significance of Red Blood Cell Alloantibodies, September 2, 2016, Dubai Clinical significance of antibodies to antigens in the Raph, John Milton Hagen, I, Globoside, Gill, Rh-associated glycoprotein, FORS, JR, LAN, Vel, CD59, and Augustine blood group systems M. Moghaddam and A.A. Naghi This article reviews information on the clinical significance and 6 shared missense mutation c.511C>T (p.Argl71Cys) as of antibodies to antigens in the Raph, John Milton Hagen, I, well as a synonymous single-nucleotide mutation (c.579A>G) Globoside, Gill, Rh-associated glycoprotein, FORS, JR, LAN, Vel, and had no clinical features. Although the CD151 protein is CD59, and Augustine blood group systems. Antibodies to many of the antigens in these groups are rarely encountered because of the critical to cell adhesion and signaling and is implicated in high prevalence of the associated antigens in most populations. cancer progression, its significance in transfusion medicine is For many of these antibodies, the clinical significance—that is, limited to only one report of a hemolytic transfusion reaction the potential to cause reduced survival of transfused antigen- 3 positive red blood cells or a transfusion reaction (e.g., anti-P, (HTR). Least-incompatible RBC units should be selected anti-Jra, and anti-Lan), and/or hemolytic disease of the fetus and for transfusion to patients with anti-MER2.2 No information newborn (e.g., anti-RHAG4 and anti-Vel)—has been documented. on anti-MER2 causing hemolytic disease of the fetus and For other antibodies, their prevalence is so rare that information newborn (HDFN) is available.4 on the clinical significance of their antibodies is not available (e.g., anti-FORS1).
    [Show full text]
  • Targeted Exome Sequencing Defines Novel and Rare Variants in Complex Blood Group Serology Cases for a Red Blood Cell Reference Laboratory Setting
    IMMUNOHEMATOLOGY Targeted exome sequencing defines novel and rare variants in complex blood group serology cases for a red blood cell reference laboratory setting Elizna M. Schoeman ,1 Eileen V. Roulis ,1 Yew-Wah Liew,2 Jacqueline R. Martin,2 Tanya Powley,2 Brett Wilson,2 Glenda M. Millard ,1 Eunike C. McGowan ,1 Genghis H. Lopez ,1 Helen O’Brien ,1 Jennifer A. Condon,3 Robert L. Flower ,1 and Catherine A. Hyland 1 he key role of a modern red blood cell (RBC) ref- BACKGROUND: We previously demonstrated that erence laboratory in transfusion medicine is to targeted exome sequencing accurately defined blood employ serology to solve complex problems. group genotypes for reference panel samples Often, the lack of appropriate RBCs, sera, or characterized by serology and single-nucleotide T polymorphism (SNP) genotyping. Here we investigate reagents makes confident resolution of a complex case the application of this approach to resolve problematic difficult. Resources can be costly and scarce, if available at serology and SNP-typing cases. all, and often require collaboration and generosity of col- 1 STUDY DESIGN AND METHODS: The TruSight One leagues from other international laboratories. In addition, sequencing panel and MiSeq platform was used for reference laboratories commonly employ single- sequencing. CLC Genomics Workbench software was nucleotide polymorphism (SNP) typing microarrays for used for data analysis of the blood group genes RBC genotyping investigations; however, these arrays are implicated in the serology and SNP-typing problem. not comprehensive in their coverage of blood groups or 2-5 Sequence variants were compared to public databases variants. When the combination of traditional serologic listing blood group alleles.
    [Show full text]
  • This Issue of Immunohematology Is Supported by a Contribution From
    Journal of Blood Group Serology and Molecular Genetics VOLUME 33, N UMBER 4, 2017 This issue of Immunohematology is supported by a contribution from Grifols Diagnostics Solutions, Inc. Dedicated to advancement and education in molecular and serologic immunohematology Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 33, Number 4, 2017 CONTENTS O RIGINAL R EP O RT 147 Assessment of common red blood cell pretreatments to yield an accurate serologic antigen phenotype compared with genotype- predicted phenotype T. Horn, J. Hamilton, J. Kosanke, V.W. Hare, W. Kluver, W. Beres, S. Nance, and M.A. Keller C ASE R EP O RT 152 Anti-Vel alloimmunization and severe hemolytic disease of the fetus and newborn K.J. Moise Jr., Y. Morales, M.F. Bertholf, S.N. Rossmann, and Y. Bai S ER O LO GI C M ETH O D R EVIEW 155 Separation of multiple antibodies by adsorption with allogeneic red blood cells E.M. Ekema O RIGINAL R EP O RT 159 Hemovigilance and the Notify Library B.I. Whitaker, D.M. Strong, M.J. Gandhi, and E. Petrisli O RIGINAL R EP O RT 165 Clinical and laboratory profile of anti-M D. Basu, S. Basu, M. Reddy, K. Gupta, and M. Chandy S ER O LO GI C M ETH O D R EVIEW 170 Dithiothreitol treatment of red blood cells C.B. Bub C omm UNI C AT I O NS 173 Thank You S. Nance and C. Flickinger 174 175 183 187 191 E R R AT U M A NN O UN C E M ENTS A DVERTISE M ENTS I NSTRU C TI O NS S UBS C RIPTI O N F O R A UTH O RS I NF O R M AT I O N E DITO R - IN -C HIEF E DITO RIAL B OARD Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Geralyn M.
    [Show full text]
  • Mission Impossible with Anti-Vel
    Mission Impossible with Anti-Vel BBTS September 2014 Stephanie Stone, Sheffield Teaching Hospitals Helen Kilgallon, NHSBT Sheffield 74 yr old female Presented to ENT May 2013: 4/52 bilateral nasal obstruction and intermittent epistaxis No B symptoms Past medical history: - Metallic mitral valve replacement 1974: Warfarin INR 3-4 - Dilated left atrium, AF, Pulmonary HTN - Angina, COPD - Type II DM, CKD stage 4, Gout, Bullous pemphygoid Social history - Retired, lives alone - 4 daughters – first in 1957 - Ex smoker - No regular ETOH - Exercise tolerance 25-40 yards - ECOG performance status 2 - Independent of activities of daily living Drug history - No known drug allergies – mild allergic reaction to blood component 2012 - Warfarin - Digoxin 125mcg od - Furosemide 40mg bd - Pravastatin 40mg on - Candesartan 8mg od - Linagliptin 5mg od - Quinine 300mg od - Betahistine 8mg tds Examination and investigations www.trialx.com Fibre optic examination: large post nasal mass – Fine needle aspiration taken 2cm cervical LN. No other palpable LN/hepatosplenomegaly/masses Hb 97 Mcv 92 Platelets 287 Wbc 6.9 Lymph 0.6 Reticulocytes 248 B12 394 Folate 8.0 Ferritin 252 Bil 10 Alt 40 Alb 44 LDH 708 DAT –ve Haptoglobin normal Immunoglobulins normal HIV/Hep B/C serology normal Bone marrow: normal Echo: good LV function, dilated LA, moderate TR, increased PA pressure CT neck, chest, abdomen and pelvis R-sided post nasal mass CT chest, abdomen and pelvis Multiple cervical and mediastinal lymph nodes Fine needle aspiration High grade cell Non Hodgkins Lymphoma:
    [Show full text]
  • Art184 Bloodgroup
    Issue 184, October 2016 www.proteinspotlight.org seeing red Vivienne Baillie Gerritsen The smallest of things can cause devastation. A word can hurt deeply. Distraction can create an accident. A spark can set off a fire. In the world of molecular biology, “small” rules. Life itself thrives on an intricate and very fragile harmony perpetuated by myriads of tiny molecules. And when something goes wrong, when a molecule changes its habits, it can create havoc. A few examples: cancer, Parkinson’s disease, Alzheimer’s and diabetes, to name but four. Blood transfusion – and even more so its effects – also depends on very small regions which themselves belong to very small molecules on the surface of each of our red blood cells. Pour the wrong kind of blood into someone, and you are in for serious complications. We all belong to a certain blood type, or group. As a consequence, we can only receive certain types of blood. Most of us have relatively common types and finding donors is usually not a problem. However, some people belong to very rare blood types, thus making blood transfusion a particularly delicate task. One of these types is known as Vel-negative. And after 60 years of scientific bafflement, it has finally been pinned down to a protein named SMIM1. shadowed until the 1920s. Today, however, Janský is credited with having been the blood group pioneer. With time it became apparent that everyone’s group is inherited, and that the success of transfusion depends on both the donor’s and the receiver’s blood type.
    [Show full text]
  • Questions in a Case of Suspected HDFN with Maternal Anti-Vel Reported
    Questions in a case of suspected HDFN with maternal anti-Vel reported Karen Rubio MT(ASCP)SBBcm Children’s Mercy Hospital Transfusion Services Laboratory Lead Technologist © The Children's Mercy Hospital 2017 1 Objectives • Review Vel | Cellano | ISBT definitions • Review of data for this case and discuss the problems • A surprise conversation 2 The “not so” usual admission • The call to evening shift • The outside Bombshell maternal results. • Pathologist on-call notified • Our results??? 3 Outside lab results Mom is R2r, O pos with anti-Vel identified in her plasma. Her phenotype at an outside facility was C-, E+, c+, e+; K+, k-; Fy(a+b+); Jk(a+-b+); M+, N- , S+, s+; Vel- Mom had a positive antibody screen with anti-Vel identified. Titers performed indicated an increase from 16 to 64 prior to delivery. 4 Outside lab results • Baby born at 39 weeks and weighed 2.96 Kg. • Meconium stained fluid noted. Apneic and floppy with agars of 2,4,7 with poor respiratory effort | Large abdomen noted with absent bowel sounds | Bronze pale skin | Thrombocytopenic | Possible sepsis with bandemia of 26% | HDFN | Hyperbilirubinemia and elevated liver enzymes | CHD | Persistent pulmonary hypertension | Generalized edema | Anemic with birth Hgb of 7 g/dL | Excessive umbilical bleeding during line insertion | CRP increasing from 0.37 to 2.32 • Cord Blood results – O pos with a negative DAT test • Transfusions – 3 syringes of Red Cells all from the same donor unit 3 syringes of platelets all from the same donor unit 2 syringes of plasma, both from the same
    [Show full text]
  • Immunohematology Case Study 2017 - #7
    Immunohematology Case Study 2017 - #7 Cinzia Paccapelo Immunohematology Reference Laboratory Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan, Italy [email protected] Clinical History Medical History: A 30 years old Caucasian female hospitalized for dorsal meningioma Transfusion history: no history of recent transfusion. Patient received 2 units of red blood cells approximately five years ago during a gynecologic surgery Pregnancy history: no history of pregnancy Serologic History . Routine serological workup was performed . The referring hospital transfusion service observed that antibody screen and identification were positive with all cells, DAT negative . Due to limited resources, a sample was submitted to Immunohematology Reference Laboratory at Policlinico Hospital of Milan (Italy) for further testing Current Sample Presentation Data ABO/Rh/K: A Rh positive, ccee, kk DAT: negative Antibody Screen Method: Indirect Antiglobulin Test (IAT) using Column Agglutination Technology (CAT) polyspecific (Biovue, Ortho Clinical Diagnostics) Antibody Screen Results: 2+ with all tested cells Antibody Identification Method: IAT using CAT-Polyspecific, polyethylene glycol (PeG), LISS and ficin-treated cells Antibody Identification Preliminary Results: all cells positive in IAT with untreated and ficin-treated red cells Antibody Identification Preliminary Results D C c E e Cw K k Fya Fyb Jka Jkb Lea Leb P1 M N S s CAT PEG 1 + + 0 + + 0 0 + 0 + 0 + 0 + + + + 0 + 2+ 2+ 2 + + 0 0 + + 0 + + 0 + 0 0 + 0 + + 0 + 2+ 2+ 3 + 0 +
    [Show full text]
  • Report of the Seoul and London Meetings
    ISBT Science Series (2016) 11, 118–122 ORIGINAL PAPER © 2016 International Society of Blood Transfusion International society of blood transfusion working party on red cell immunogenetics and terminology: report of the Seoul and London meetings J. R. Storry,1,* L. Castilho,2 Q. Chen,3 G. Daniels,4 G. Denomme,5 W. A. Flegel,6 C. Gassner,7 M. de Haas,8 C. Hyland,9 M. Keller,10 C. Lomas-Francis,11 J. M. Moulds,12 N. Nogues,13 M. L. Olsson,14 T. Peyrard,15 C. E. van der Schoot,16 Y. Tani,17 N. Thornton,18 F. Wagner,19 S. Wendel,20 C. Westhoff11 & V. Yahalom21 1Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden 2University of Campinas/Hemocentro, Campinas, Brazil 3Jiangsu Province Blood Center, Nanjing, China 4Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, UK 5Blood Center of Wisconsin, Milwaukee, WI, USA 6Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, USA 7Blutspende Zurich, Zurich, Switzerland 8Sanquin Blood Supply Foundation, Amsterdam, The Netherlands 9Australian Red Cross Blood Services, Brisbane, Qld,Australia 10American Red Cross Blood Services, Philadelphia, PA, USA 11New York Blood Center, New York, NY, USA 12Grifols, San Marcos, TX, USA 13Banc de Sang i Teixits, Barcelona, Spain 14Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden 15Institut National de la Transfusion Sanguine, Departement Centre National de Reference pour les Groupes Sanguins,
    [Show full text]
  • Vel Blood Group System: a Review J.R
    Journal of Blood Group Serology and Molecular Genetics VOLUME 33, N UMBER 2, 2017 This issue of Immunohematology is supported by a contribution from Grifols Diagnostics Solutions, Inc. Dedicated to advancement and education in molecular and serologic immunohematology Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 33, Number 2, 2017 CONTENTS C ASE R EPO R T 51 Hematologic complications in a patient with Glycine soja polyagglutination following fresh frozen plasma transfusion R.P. Jajosky, L.O. Cook, E. Manaloor, J.F. Shikle, and R.J. Bollag R EVIEW 56 The Vel blood group system: a review J.R. Storry and T. Peyrard C ASE R EPO R T 60 Two cases of the variant RHD*DAU5 allele associated with maternal alloanti-D J.A. Duncan, S. Nahiriniak, R. Onell, and G. Clarke R EVIEW 64 The FORS awakens: review of a blood group system reborn A.K. Hult and M.L. Olsson C ASE R EPO R T 73 A suspected delayed hemolytic transfusion reaction mediated by anti-Joa R.P. Jajosky, W.C. Lumm, S.C. Wise, R.J. Bollag, and J.F. Shikle R EVIEW 76 Recognizing and resolving ABO discrepancies G.M. Meny B OOK R EVIEW 82 Bloody Brilliant: A History of Blood Groups and Blood Groupers S. Gerald Sandler 84 90 94 96 A NNOUN C EMENTS A DVE R TISEMENTS I NST R U C TIONS S U B S cr IPTION FO R A UTHO R S I NFO R M AT I O N E DITO R - IN -C HIEF E DITO R IAL B OA R D Sandra Nance, MS, MT(ASCP)SBB Philadelphia, Pennsylvania Patricia Arndt, MT(ASCP)SBB Geralyn M.
    [Show full text]